Crossmark

Design and Evaluation of β-Cyclodextrin-Modified Warfarin-Chitosan and Warfarin-Silica Composites for Controlled Drug Release: In Vitro and in Vivo Approach

Crossref DOI link: https://doi.org/10.1007/s12247-025-10313-z

Published Online: 2026-01-09

Published Print: 2026-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hussain, Amna

Tan, Wen-Nee

Hussain, Abdullah Ijaz

Fatima, Tabinda

Haji, Esraa M

Almutairy, Ali F

Alnasser, Sulaiman Mohammed Abdullah

Alghamdi, Hajar

Alanezi, Abdulkareem A.

Ahmad, Ashfaq
Funding

Funding for this research was provided by:

Deputyship for Research & Innovation, Ministry of Education in Saudi Arabia (0029-1446-S.)
License Information

Text and Data Mining valid from 2026-01-09

Version of Record valid from 2026-01-09
More Information

Article History

Received: 25 September 2025

Accepted: 7 December 2025

First Online: 9 January 2026

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below